Frost & Sullivan Honors Xoft for Oncology Innovation

Innovative and Cost-Effective Axxent(R) Electronic Brachytherapy System
Positions Xoft, Inc. at the Forefront of Oncology Advancement

SUNNYVALE, Calif., July 23 /PRNewswire/ -- Xoft, Inc. today announced that
Frost & Sullivan has bestowed the 2008 North American Medical Devices
Healthcare Innovation Award in Oncology to Xoft. Recognizing excellence in
the development of the Axxent(R) Electronic Brachytherapy System, the Frost &
Sullivan Award highlights Xoft's ability to develop advanced oncology products
to fit the growing needs of the medical devices industry.
"Through the creation of innovative and cost-effective solutions, Xoft is
positioning itself at the forefront of oncology with a broad-based treatment
platform with special emphasis on women's health," said Frost & Sullivan
Industry Analyst Sheila Ewing. "Frost & Sullivan believes that the
outstanding dedication to product research and development initiatives
implemented by Xoft will both rapidly grow the company's market penetration as
well as positively impact the quality of healthcare in the U.S. Xoft is poised
to continue its growth in the market and gain additional market share in the
years ahead."
At the end of 2007, Xoft began commercialization of the Axxent Electronic
Brachytherapy System, a suite of innovative devices to deliver targeted
radiation therapy directly to tumor sites using a micro-miniature X-ray source
rather than radioactive isotopes. The technology allows treatment to be
delivered with fewer logistical issues in minimally-shielded clinical
settings. It also allows medical personnel to be present during treatment
delivery, minimizing patient anxiety. This stands in stark contrast to
existing radiation therapy alternatives which require patient isolation in a
heavily-shielded vault.
Xoft also recently announced the launch of the EXIBT Study (Electronic
Xoft Intersociety Brachytherapy Trial), a national Electronic Brachytherapy
patient registry under the oversight of three national physician societies,
the American Brachytherapy Society (ABS), the American Society of Breast
Surgeons (ASBrS), and the American College of Radiation Oncology (ACRO). With
an enrollment goal of 400 patients, the objective of the multi-center study is
to assess the long-term effects of the Axxent(R) System for the accelerated
treatment of early stage breast cancer patients, bringing treatment time down
from 6-8 weeks to 5 days.
"Coming on the heels of the launch of the patient registry, the recent FDA
clearance of our applicators for the treatment of endometrial cancer, and
expanded FDA clearance for use of the Axxent System in the radiation therapy
of other cancers, the Frost & Sullivan Award continues to provide validation
of Xoft's broad-based oncology treatment platform," said Michael Klein,
president and CEO of Xoft.
"Additionally, the Axxent System aligns well with recent directives from
the Federal Government and the Nuclear Regulatory Commission recommendations
to the National Academy of Sciences to evaluate appropriate alternative
technologies for the replacement of radiation sources that may pose a national
security risk. According to the NAS, the majority of these sources are
radioactive isotopes used in medical applications. Because the Axxent System
uses an electronic source, the technology can mimic the therapeutic value of
certain isotopes while mitigating such national security concerns,
representing a very viable alternative for some cancers. Recently completed
and ongoing clinical studies combined with industry validation, such as the
Frost & Sullivan award, set the foundation to dramatically expand access to
this essential and clinically proven alternative for cancer treatment," added
Klein.
About Axxent Electronic Brachytherapy
The Axxent(R) Electronic Brachytherapy System has been developed to
address a variety of oncological and non-oncological indications. The
proprietary Axxent treatment platform is cleared for use in the treatment of
cancers or conditions where radiation therapy is indicated. Specific
applicators have been cleared for treatment of early stage breast cancer and
endometrial and rectal indications. Designed to deliver electronic, X-ray-
based radiation treatment, the Axxent System can be used in virtually any
clinical setting under the supervision of a radiation oncologist. It is
designed to deliver non-radioactive therapy directly to cancer sites with
minimal radiation exposure to surrounding healthy tissue. Eliminating the need
for heavily shielded environments, it gives radiation oncologists the
flexibility to deliver therapy in a broader range of clinical settings without
the complex handling and resource logistics necessary when performing
brachytherapy using radioactive isotopes. As a result, tens of thousands of
patients annually will have greater access to therapy that is delivered more
easily and conveniently.
About Xoft, Inc.
Founded in 1998, Xoft develops leading-edge technologies for the practice
of radiation oncology through Electronic Brachytherapy, which utilizes
proprietary miniaturized X-ray tube technology. The Axxent(R) Electronic
Brachytherapy System, Xoft's first treatment system, is currently being used
in Accelerated Partial Breast Irradiation (APBI) for the treatment of
early-stage breast cancer and in the treatment of endometrial cancer. For more
information, visit http://www.xoftinc.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to
accelerate their growth. The company's TEAM Research, Growth Consulting, and
Growth Team Membership(TM) empower clients to create a growth-focused culture
that generates, evaluates, and implements effective growth strategies. Frost &
Sullivan employs over 45 years of experience in partnering with Global 1000
companies, emerging businesses, and the investment community from more than 30
offices on six continents. For more information about Frost & Sullivan's
Growth Partnership Services, visit http://www.awards.frost.com.
Axxent is a registered trademark of Xoft, Inc.
SOURCE Xoft, Inc.

Chris K. Joseph of Xoft, Inc., +1-510-339-2293, chris@ckjcomm.com; or Jake
Wengroff of Frost & Sullivan, +1-210-247-3806, jake.wengroff@frost.com